Blueprint Medicines Corp (BPMC)
87.46
-1.78
(-1.99%)
USD |
NASDAQ |
Oct 31, 16:00
87.46
0.00 (0.00%)
After-Hours: 20:00
Blueprint Medicines Accounts Receivable (Quarterly): 85.06M for June 30, 2024
Accounts Receivable (Quarterly) Chart
Historical Accounts Receivable (Quarterly) Data
Date | Value |
---|---|
June 30, 2024 | 85.06M |
March 31, 2024 | 60.05M |
December 31, 2023 | 42.83M |
September 30, 2023 | 40.86M |
June 30, 2023 | 35.15M |
March 31, 2023 | 30.01M |
December 31, 2022 | 23.52M |
September 30, 2022 | 19.32M |
June 30, 2022 | 27.12M |
March 31, 2022 | 28.76M |
December 31, 2021 | 25.16M |
September 30, 2021 | 18.40M |
Date | Value |
---|---|
June 30, 2021 | 25.47M |
March 31, 2021 | 34.66M |
December 31, 2020 | 7.096M |
September 30, 2020 | 44.37M |
June 30, 2020 | 3.403M |
March 31, 2020 | 4.51M |
December 31, 2019 | 0.663M |
September 30, 2019 | 2.414M |
June 30, 2019 | 0.75M |
March 31, 2019 | |
December 31, 2018 | 0.064M |
Accounts Receivable Definition
Account used to record sales made "on account", meaning that the company has made a sale but has not collected payment. When company collects cash as payment, the corresponding account receivable is decreased.
Accounts Receivable (Quarterly) Range, Past 5 Years
0.663M
Minimum
Dec 2019
85.06M
Maximum
Jun 2024
29.28M
Average
27.12M
Median
Jun 2022
Accounts Receivable (Quarterly) Benchmarks
Biomarin Pharmaceutical Inc | 777.55M |
Boston Scientific Corp | 2.40B |
Masimo Corp | 337.70M |
Regeneron Pharmaceuticals Inc | 5.717B |
NovaBay Pharmaceuticals Inc | 0.547M |